---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-23-000041"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:27:27.930637+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Maravai LifeSciences shareholders elect three Class III directors at 2023 annual meeting

## Summary
- Anat Ashkenazi, Gregory T. Lucier, and Luke Marker elected as Class III directors with over 183M votes each.
- Ratification of Ernst & Young as independent auditor for 2023 passed with 234,840,684 votes for, 15,103 against.
- Non-binding advisory vote on executive compensation approved: 221,869,456 for, 8,907,696 against.
- Quorum present: 234,865,441 of 250,882,769 outstanding shares, representing approximately 93.6%.

## SEC filing metadata
- accession: 0001823239-23-000041
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000041/0001823239-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000041/mrvi-20230518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-23-000041
- JSON: https://secwatch.observer/filing/0001823239-23-000041.json
- Plain text: https://secwatch.observer/filing/0001823239-23-000041.txt

## Key facts
- Shareholder Votes
  MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2023-05-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal No. 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's Proxy Statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 221,869,456 8,907,696 27,642 4,060,647
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000041/0001823239-23-000041-index.htm
- Shareholder Votes
  MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Election of directors at the 2023-05-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal No. 1: Election of directors. The Company’s shareholders elected the following nominees for director to serve as Class III directors for a three-year term expiring at the Company’s 2026 annual meeting of shareholders and until their successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Anat Ashkenazi 186,578,234 44,226,560 4,060,647 Gregory T. Lucier 186,046,648 44,758,145 4,060,648 Luke Marker 183,198,145 47,606,648 4,060,648
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000041/0001823239-23-000041-index.htm
- Shareholder Votes
  MARAVAI LIFESCIENCES HOLDINGS, INC. shareholders approved Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-18
  source text: Proposal No. 2: Proposal to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was ratified. Votes For Votes Against Abstentions 234,840,684 15,103 9,654
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000041/0001823239-23-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.